A new pilot partnership between the National Institutes of Health Clinical Center, the National Cancer Institute's Center for Cancer Research, and the Damon Runyon Cancer Research Foundation will offer some of the capabilities and expertise of America's research hospital to an external group of clinical investigators in cancer research. The special talent and resources of the NIH will allow Damon Runyon-funded investigators to undertake studies and collaborations that will advance understanding of the prevention, diagnosis, and treatment of cancer.
Damon Runyon Clinical Investigators (DRCIs) are early career physician-scientists whose focus is on the translation of basic science discoveries into practical therapies. Since 1946, the Damon Runyon Cancer Research Foundation has invested more than $230 million in early career cancer researchers who have the energy, drive, and creativity to become leading innovators in their fields.
"Thanks to the new three-component partnership, these young investigators can apply to use certain equipment, facilities, and patient cohorts at the Clinical Center in research collaborations with NIH clinician-scientists," said John I. Gallin, M.D., Clinical Center director.
An approved research proposal could also provide access to select research materials, services, or products that may not be available or possible at their home institutions such as products from the Pharmacy Department's Pharmaceutical Development Facility through arrangements with the Clinical Center but without a formal research collaboration with a specific institute.
If the pilot proves successful, the NIH and the Clinical Center may pursue similar partnerships with other NIH institutes and centers and external organizations.
"This is a first step toward opening the doors of the Clinical Center to a new band of clinician-scientists, further supporting the NIH mission to enhance health and reduce the burden of dise
|Contact: Yung S. Lie|
Damon Runyon Cancer Research Foundation